AAN 2016 General News

An extended release formulation of molindone shows promise as an adjunctive treatment for refractory impulsive aggression among children administered stimulant monotherapy for ADHD.

Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in higher rates of total migraine freedom.

Deflazacort and prednisone improved biomarkers of muscle breakdown versus placebo in boys with Duchenne muscular dystrophy, according to results of a randomized Phase 3 study reported at the 68th AAN Annual Meeting.

Suvorexant (20mg/15mg and 40mg/30mg) improves sleep for patients with insomnia and reduces the impacts of insomnia on patients’ daytime functioning, as assessed using the Insomnia Severity Index questionnaire.

Once-daily valbenazine 25 to 75mg for 6 weeks significantly reduced severity of tardive dyskinesia in patients with schizophrenia, schizoaffective disorder, depression, and bipolar disorder.

The “most comprehensive clinical description of antibiotic-associated encephalopathy” has found that “different antibiotics likely have varying patterns of toxicity,” a review has found.

For patients with medication overuse headaches, discontinuation of overused medication and addition of preventive medication offers the best current treatment, results presented at the 68th AAN Annual Meeting have found.

The investigational vesicular monoamine transporter 2 (VMAT2) inhibitor deutetrabenazine (SD-809) can be administered “without regard to the type of meal consumed,” according to authors of a small bioavailability study presented at the 68th Annual AAN Meeting.

A higher dosage of abobotulinumtoxinA (Dysport; Ipsen Biopharmaceuticals) was found to significantly improve the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score in patients with cervical dystonia (CD), according to a study presented at the 68th AAN Annual Meeting.

Treatment with oral dexamethasone for 4 days significantly improved pain levels in the majority of outpatients with status migrainosus, a retrospective chart review presented at the 68th AAN Annual Meeting has found.